NEW YORK (GenomeWeb News) – Cepheid reported after the close of the market Thursday that its third-quarter revenues increased 15 percent and were in line with a pre-announcement the firm made regarding the quarter late last month.

The Sunnyvale, Calif.-based molecular diagnostics firm reported total revenues of $80.5 million for the three months ended Sept. 30, up from $70.2 million for the third quarter of 2011. Wall Street analysts, on average, expected revenues of $81 million.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Jul
24
Sponsored by
Qiagen

In this webinar, Dr. Fergus Couch from the Mayo Clinic will present data from a large study that used a targeted sequencing panel to determine pancreatic cancer risk associated with inherited mutations in several cancer predisposition genes.

Jul
25
Sponsored by
Streck

This online seminar will discuss the advantages of incorporating molecular testing into the microbiology laboratory to aid in the identification of relevant antibiotic resistance mechanisms. 

Aug
09

In this two-part webinar, Dr. Elin Gray, from Edith Cowan University, and Ms. Weiwei Zhao, from Kingmed diagnostic, will compare the highly sensitive, multiplexed UltraSEEK technology, on the MassARRAY system, to digital droplet PCR (ddPCR) results on melanoma and non-small cell lung carcinoma samples.